Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HCC

- PMLiVE

AstraZeneca’s Imfinzi combination shows promise in phase 3 liver cancer study

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

- PMLiVE

AstraZeneca shares positive phase 3 results for Imfinzi combination in liver cancer

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as subcutaneous formulation

Eisai said it aims to apply for US approval of SC Leqembi by the end of March 2024

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as a subcutaneous formulation

Leqembi was granted traditional approval in the US earlier this month as a bi-weekly intravenous infusion

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug granted full FDA approval

Leqembi was granted accelerated approval earlier this year for patients with early Alzheimer's disease

- PMLiVE

AstraZeneca’s phase 3 liver cancer study shows continued survival benefit

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug backed by FDA advisory committee for traditional approval

Leqembi was granted accelerated approval by the FDA in January for patients with early AD

- PMLiVE

MSD and Eisai’s combination therapy recommended by NICE for advanced endometrial cancer

More than 9,700 people are diagnosed with womb cancer each year in the UK

- PMLiVE

Roche reports positive phase 3 data for Tecentriq combination in liver cancer

More than 900,000 people are diagnosed with the disease globally each year

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug associated with positive long-term health outcomes

A simulation model estimated lecanemab to potentially slow the rate of disease progression

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration

US veterans in the early stages of the disease who meet VHA criteria will be eligible for coverage

- PMLiVE

FDA grants priority review for traditional approval of Biogen and Eisai’s Alzheimer’s drug

Leqembi was granted accelerated approval in the US earlier this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links